Thromb Haemost 1989; 61(02): 294-297
DOI: 10.1055/s-0038-1646579
Original Article
Schattauer GmbH Stuttgart

Heparin Inhibition of Endotoxin-Dependent Limulus Amebocyte Lysate Coagulation[*]

Authors

  • James A Marcum

    The Marine Biological Laboratory Woods Hole, MA; the Department of Pathology, Harvard Medical School, Boston, MA; the Department of Biology, MIT, Cambridge, MA; and the Departments of Laboratory Medicine and Medicine, University of California School of Medicine, San Francisco, CA, USA
  • Jack Levin

    The Marine Biological Laboratory Woods Hole, MA; the Department of Pathology, Harvard Medical School, Boston, MA; the Department of Biology, MIT, Cambridge, MA; and the Departments of Laboratory Medicine and Medicine, University of California School of Medicine, San Francisco, CA, USA
Further Information

Publication History

Received 11 November 1988

Accepted after revision 18 November 1988

Publication Date:
30 June 2018 (online)

Preview

Summary

Addition of commercial heparin to preparations of the coagulation system obtained by hypotonic lysis of Limulus amebocytes, prior to the addition of endotoxin from gram-negative bacteria, inhibited gelation. Activation of the cell-lysate proclotting enzyme, utilizing a diluted lysate preparation and synthetic substrates, was inhibited to a comparable extent with either anticoagulantly active or inactive heparin. Other glycosaminoglycans, including heparan sulfate, dermatan sulfate, chondroitin 4-sulfate, and chondroitin 6-sulfate, did not inhibit the generation of clotting enzyme activity. Experiments conducted with preparations of proactivator(s) and proclotting enzyme, obtained by fractionation of lysate with heparin-Sepharose, revealed that inhibition of endotoxin-dependent activation of amebocyte lysate by heparin is mediated by precipitation of the proactivator(s) and can be prevented by increasing the salt concentration.

Supported, in part, by a Summer Fellowship (Marine Biological Laboratory, Woods Hole, MA) awarded to J.A.M.; Research Grants HL34800 and HL31035 from the National Heart, Lung, and Blood Institute, N. I. H., Bethesda, MD; and the Veterans Administration.